Skip to content
biotechnology hero image
biotechnology hero image

Biotechnology

Our team regularly advises clients developing biotech products in areas including biotechnology derived proteins (such as insulin), immunologicals (such as vaccines and allergens), blood or plasma derived products, and engineered tissues.

Our team benefits from having several members of the group who have completed degrees in subjects including molecular biology, biochemistry and genetics. This knowledge enables us to quickly grasp technical concepts and provide nuanced and tailored advice.

We closely follow new developments and emerging trends in the biotech market. For example, we have been following the emerging regulatory pathways for biosimilars and advising clients on appropriate strategies.

We have worked with many well-known companies on their biological products, including Pfizer, Novartis, Regeneron, Amgen and Roche.

News and insights

blurred lights in a tunnel

Publications: 02 February 2023

Podcast: Sanctions outlook 2023

Sanctions began dominating the headlines again in 2022. Largely, reports focused on the ongoing sanctions targeting Russia. As we look ahead to 2023, Russia remains a target. Other countries (such as…

Read more
Lab worker using syringe

Blog Post: 01 February 2023

Clinical Trial Regulation: Balancing Transparency Requirements and Protection of CCI – new Q&A published

The Clinical Trial Regulation (EU) No 536/2014 (CTR) became fully applicable yesterday (31 January), following the end of the transition period. Therefore, the use of the Clinical Trial Information…

Read more
Long exposure shot of traffic lights moving over a road.

Publications: 10 January 2023

The EU and UK adopt further sanctions against Russia

At the close of 2022, and with the war in Ukraine entering its tenth month, the EU and the UK adopted further sanctions packages against Russia. The latest sanctions packages include further asset…

Read more
Cell with needle

Blog Post: 23 March 2022

New decisions in Europe and the US in CRISPR/Cas9 patent dispute

CRISPR/Cas technology, also known as “genetic scissor”, is one of the most targeted and promising tools in gene technology. It allows targeted and extremely precise modification of the DNA in humans,…

Read more

Download our sector brochure

Life sciences A&O red molecules

Our Life Sciences and Healthcare sector focus 2022

Our global Life Sciences and Healthcare sector comprises a multi-disciplinary team. We act for companies and their investors across the industry, including in the pharmaceuticals, biotech, animal health, consumer health, med tech, and diagnostics sectors.